A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs

The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *